Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study

Maximizing Opportunities and Avoiding Mistakes in Triple Therapy for Hepatitis C Virus

(2012) A. Sidney Barritt et al.   GASTROENTEROLOGY

Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II study

(2012) Michael P. Manns et al.   HEPATOLOGY

8 SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)

(2012) C. Hezode et al.   JOURNAL OF HEPATOLOGY

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study

(2012) Christophe Moreno et al.   JOURNAL OF HEPATOLOGY

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial

(2011) Michael Manns et al.   ANTIVIRAL THERAPY

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

(2011) Marc G. Ghany et al.   HEPATOLOGY

Host genomics and HCV treatment response

(2011) Paul J Clark et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow

(2011) Tarik Asselah et al.   LIVER INTERNATIONAL

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

(2011) Kenneth E. Sherman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

(2011) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435

(2010) O. Lenz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

(2010) Alexander J. Thompson et al.   GASTROENTEROLOGY

Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study

(2010) Andri Rauch et al.   GASTROENTEROLOGY

In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor

(2009) T.-I Lin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

(2009) Henk W. Reesink et al.   GASTROENTEROLOGY

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

(2009) Dongliang Ge et al.   NATURE

IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

(2009) Vijayaprakash Suppiah et al.   NATURE GENETICS

Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C

(2009) Yasuhito Tanaka et al.   NATURE GENETICS

Diagnosis, management, and treatment of hepatitis C: An update

(2008) Marc G. Ghany et al.   HEPATOLOGY